Archive

Galapagos to review future of Jyseleca

Written by Charlie King | 8 Aug 2023

Galapagos revealed that it is weighing up all options for its only approved product, the JAK inhibitor Jyseleca. Galapagos has disclosed its financials for the first half 2023… read more.

Managing anxiety and depression in arthritis

Written by Charlie King | 5 Jun 2023

Anxiety and depression are the mental health issues most commonly associated with inflammatory arthritis, and it is well-established that there is a link between mental health issues and… read more.

New breakthrough in the treatment of rheumatoid arthritis

Written by Charlie King | 3 Feb 2023

A research team, led by Professor Sung Ho Park in the Department of Biological Sciences at UNIST announced the results of a study on osteoblasts that damage joint bones… read more.

Common workplace fumes and dusts may heighten rheumatoid arthritis risk

Written by Charlie King | 9 Dec 2022

Breathing in common workplace dusts and fumes from agents such as vapours, gases, and solvents, may heighten the risk of developing rheumatoid arthritis, suggests research published online in… read more.

One in five patients with rheumatoid arthritis were undiagnosed during the pandemic

Written by Charlie King | 6 Nov 2022

The number of new diagnoses of rheumatoid arthritis fell by 20% in the first year of the COVID-19 pandemic, new research suggests. The study, published today in The Lancet… read more.

Findings support repurposing rheumatoid arthritis drug auranofin for diabetes

Written by Charlie King | 20 Oct 2022

Researchers at Baylor College of Medicine and collaborating institutions discovered that the rheumatoid arthritis drug auranofin can potentially be repurposed to improve diabetes-associated symptoms. The study, which was… read more.

Key protein that drives rheumatoid arthritis damage

Written by Charlie King | 28 Sep 2022

Scientists have identified a protein known as sulfatase-2 that plays a critical role in the damage caused by rheumatoid arthritis. A chronic disease in which the immune system… read more.

FDA accepts for review supplemental application for Abrilada interchangeability – Pfizer

Written by Charlie King | 5 Jun 2022

Pfizer Inc. announced that the FDA has accepted for review the Prior Approval Supplement (PAS) to the Biologics License Application (BLA) for Abrilada (adalimumab-afzb) as an interchangeable biosimilar… read more.

New study shows genes can predict response to arthritis treatment and paves the way for future drug development

Written by Charlie King | 31 May 2022

New research from Queen Mary University of London, published in Nature Medicine, has shown that molecular profiling of the diseased joint tissue can significantly impact whether specific drug treatments will… read more.

Older adults with rheumatoid arthritis still undermedicated, despite aggressive guidelines

Written by Charlie King | 27 May 2022

Despite guidelines that call for early and aggressive treatment of rheumatoid arthritis, a new study suggests many older adults are not prescribed disease-modifying medications for their inflammatory autoimmune… read more.

Rheumatoid arthritis drug cuts mortality among COVID-19 ventilated patients

Written by Bruce Sylvester | 19 Feb 2022

Critically ill COVID-19 patients already on mechanical ventilation or extracorporeal membrane oxygenation have achieved a significantly higher rate of survival when randomized to receive baricitinib, a treatment for… read more.

AbbVie provides update on Rinvoq for the treatment of rheumatoid arthritis in the U.S

Written by Charlie King | 30 Jan 2022

AbbVie announced an update to the U.S. Prescribing Information and Medication Guide for Rinvoq (upadacitinib) for the treatment of adults with moderate to severe rheumatoid arthritis (RA). This… read more.

« Previous 1 2 3 Next »

Archive

Subscribe for our mailing list

Follow Us